Michael Goodman, M.D., F.A.C.P., Curriculum Vitae - Glacier Oncology

Recommendations

Info

antibody production and in vitro release of IL-1. J. Immunol 142: 1107,1989.72. Goodman, M.G. Demonstration of receptors specific for 7,8-disubstituted guanineribonucleosides in murine B lymphocytes. J. Biol. Chem. 265:22467,1990.73. Goodman, M.G., and D.M. Cherry. Ligand binding sites for a synthetic B cell growth anddifferentiation factor. Cell. Immunol. 123:417,1989.74. Goodman, M. G., L. Speizer, G. Bokoch, J. Kanter, and L. L. Bnmton. Activity of anintracellular lymphocyte stimulator is independent of G-protein interactions, [Ca2+]j elevation,phosphoinositide hydrolysis, and protein kinase C translocation. J. Biol. Chem. 265:12248,1990.75. Goodman, M.G. B lymphocytes from hyporesponsive SJL mice contain aberrant nucleosidereceptors. Cell. Immunol 129: 377, 1990.76. Goodman, M.G., S. Gupta, M.E. Rosenthale, R.J. Capetola, S.C. Bell, and W.O. Weigle.Protein kinase C independent restoration of specific immune responsiveness in commonvariable immunodeficiency. Clinical Immunology and Immunopathology 59:26,1991.77. Goodman, M.G. Cellular and biochemical studies of substituted guanine ribonucleosideimmunostimulants. Immunopharmacol. 21:51. 1991.78. Pope, B.L., J. Sigindere, E. Chourmouzis, and M.G. Goodman. 7-allyl-8-oxoguanosine(loxoribine) inhibits the metastasis of B16 melanoma cells and has adjuvant activity in miceimmunized with a B16 tumor vaccine. Cancer Immunol. Immunother. 38:83,1994.79. Chen, R., M. G. Goodman, D. Argentieri, S. C. Bell, L. E. Burr, J. Come, J. H. Goodman,D.H. Klaubert, BE Maryanoff, B.L. Pope, MS Rampulla, MR Schott, and AB Reitz.Guanosine deriv-atives as immunostimulants. Discovery of loxoribine. Nucleosides &Nudeotides 13:551, 199480. Goodman, M. G., and J. H. Goodman. Topology of the loxoribine binding site: studies withinactive loxoribine analogues. J. Immunol, 153: 4081-4087,1994.81. Pope, B.L., E. Chourmouzis, J.P. Maclntyre, S. Lee, and M.G. Goodman. Murine strainvariation in the natural killer cell and proliferative responses to the immunostimulatorycompound 7-allyl-8-oxoguanosine: role of cytokines. Cell. Immunol. 159:194, 1994.82. A.B. Reitz, M.G. Goodman, B. Pope, L. Burr, E. Chourmouzis, J. Come, D. Klaubert, B.Maryanoff, M.E. McDonnell, M.S. Rampulla, M.R. Schott, J.H. Goodman, and R. Chen.Small-molecule immunostimulants: Synthesis and activity of 7,8-disubstituted guanosinesand structurally related compounds. J. Med. Chem. 37:3561,1994.14
83. Goodman, M. G., S. Wormsley, J. C. Spinosa, and L.D. Piro. Loxoribine induces ChronicLymphocytic Leukemia B cells to traverse the cell cycle. Blood, 84:3457-3464,1994.84. McKee, D., M.G. Goodman, and L.D. Piro. The Interferons in Hematological Malignancies.Expert Opinion in Investigational Drugs, 13:1, 1994.85. Pope, B.L., E. Chourmouzis, S. Lee, and M.G. Goodman. Enhancement of immunostimulatoryactivity by dual substitution of CS-substituted guanine ribonucleosides:correlation with increased cytokine secretion. J. Immunotherapy, 17:98-108,1995.86. Rivas, A., Tintle, L., Argentieri, D., Kimball, E., Goodman, M., Anderson, D., Capetola, R.,Quimby, F. A primary immunodeficiency syndrome in Shar-pei dogs. Clin. Immunol.Immunopath., 74:243-251,1995.87. Pope, B. L., J. P. Maclntyre, E. Kimball, S. Lee, L. Zhou, R. Gareth, and M. G. Goodman.The immunostimulatory compound 7-allyl-8-oxoguanosine (Loxoribine) induces a distinctsubset of murine cytokines. Cell. Immunol. 162:333-339,1995.88. Goodman, M.G. A new approach to vaccine adjuvants: Immunopotentiation by intracellularT helper-like signals transmitted by Loxoribine. In "Vaccine Design: the subunit andadjuvant approach", M. F. Powell and M.J. Newman, Eds. Plenum Press, New York, N.Y.pp. 581-609,1995.89. Pope, B.L. and M. G. Goodman. Synthetic guanine ribonucleosides as immunostimulants.In "Immimopharmaceuticals", E. Kimball, Ed. CRC Press, Boca Raton, FL. pp. 167-192,1995.90. Goodman, M.G., A.B. Reitz, R. Chen, M.D. Bobardt, J.H. Goodman, and B.L.Pope.Selective modulation of elements of the immune system by low molecular weight nucleosides.J. Pharmacology and Experimental Therapeutics, 274:1552, 1995.91. Goodman, M.G., S. Wormsley, L. Piro, A. Saven, and J. Spinosa. New perspectives on theapproach to Chronic Lymphocytic Leukemia. Leukemia andLymphoma, 18:179, 1995.92. Goodman, M.G., Bobardt, M.C., and Goodman, J.H. B cell receptor-mediated signalingdespite protein tyrosine kinase disruption: Signal salvage by 7-allyl-8-oxoguanosine.Submitted for publication.93. Goodman, M.G., Strahl, D.M., Bobardt, M.D., M. McDonald, A. B. Reitz and J. H.Goodman. Initial characterization of proteins mediating B cell activation by 7,8-disubstitutedguanine ribonucleosides. Submitted for publication.15
Page 1 and 2: CURRICULUM VITAEMichael Gordon Good
Page 3 and 4: Diplomate, American Board of Intern
Page 5 and 6: 3. Immunophenotypic and Functional
Page 7 and 8: (continued)11. Goodman, M.G., and W
Page 9 and 10: 12. Goodman, M.G. and W.O. Weigle.
Page 11 and 12: esistance to metabolic processing b
Page 13: L.F. Thompson and R.W.E. Watts, eds
Page 17 and 18: 11. Goodman, M.G. and W.O. Weigle.
Page 19 and 20: McKee, D, Earth, N, Guthiel, J. Com
Page 21: new and developing treatments for C

Michael Goodman, M.D., F.A.C.P., Curriculum Vitae - Glacier Oncology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?